Targeted inhibition of ACLY expression to reverse the resistance of sorafenib in hepatocellular carcinoma

Resistance to sorafenib has been documented in hepatocellular carcinoma (HCC) patients. We investigated: (i) the correlation between adenosine triphosphate citrate lyase (ACLY) expression and sorafenib resistance in HCC; and (ii) if targeted inhibition could reverse sorafenib resistance. Samples of HCC tissue were obtained from patients and ACLY expression was measured. PET/CT was employed to measure maximum standard unit value (SUVmax) in HCC patients before and after sorafenib treatment. Using HepG2 cells, we created a sorafenib-resistant cell line. Glucose metabolism and lipid synthesis in HCC cells were tested using 14C-glucose. Disulfide-crosslinked polyethylenimine (SS-PEI)-mediated plasmid transfection was carried out, followed by creation of an HCC model in mice. SUVmax of HCC lesions was closely related to ACLY expression. Patients with high ACLY expression were not sensitive to sorafenib therapy. Lipid metabolism was more active in sorafenib-resistant HCC cells. ACLY expression was higher in sorafenib-resistant cells and HCC-cell sensitivity to sorafenib increased after ACLY-knockout. The latter reversed sorafenib resistance in HCC cells more significantly under hypoxic conditions. SS-PEI/proline-modified short hairpin-(psh)RNA-ACLY plus sorafenib inhibited the growth of drug-resistant cells significantly. These data suggest that ACLY downregulation can reverse sorafenib resistance, and that SS-PEI can be used to mediate shRNA-ACLY transfection in HCC treatment.

[1]  Belén G. Sánchez,et al.  Dysregulated lipid metabolism in hepatocellular carcinoma cancer stem cells , 2020, Molecular Biology Reports.

[2]  Kang-Tao Wang,et al.  Magnesium intake and primary liver cancer incidence and mortality in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial , 2020, International journal of cancer.

[3]  D. Calvisi,et al.  Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma , 2019, Front. Oncol..

[4]  L. Fournel,et al.  ATP citrate lyase: a central metabolic enzyme in cancer. , 2019, Cancer letters.

[5]  Ge Liu,et al.  Sorafenib kills liver cancer cells by disrupting SCD1‐mediated synthesis of monounsaturated fatty acids via the ATP‐AMPK‐mTOR‐SREBP1 signaling pathway , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  B. Delabarre,et al.  An allosteric mechanism for potent inhibition of human ATP-citrate lyase , 2019, Nature.

[7]  Zi-fang Song,et al.  Supplementary Sorafenib Therapies for Hepatocellular Carcinoma—A Systematic Review and Meta-Analysis , 2019, Journal of clinical gastroenterology.

[8]  C. Blanchet,et al.  Structure of ATP citrate lyase and the origin of citrate synthase in the Krebs cycle , 2019, Nature.

[9]  A. Monto,et al.  Screening for Hepatocellular Carcinoma to Improve Cancer-Related Mortality: Looking Behind When We Should Be Looking Ahead. , 2019, Gastroenterology.

[10]  Li Yang,et al.  Combinatorial treatment of Rhizoma Paridis saponins and sorafenib overcomes the intolerance of sorafenib , 2018, The Journal of Steroid Biochemistry and Molecular Biology.

[11]  Carlotta Granchi,et al.  ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism. , 2018, European journal of medicinal chemistry.

[12]  G. Chen,et al.  New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies. , 2017, Biochimica et biophysica acta. Reviews on cancer.

[13]  I. Ng,et al.  Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation. , 2017, Journal of hepatology.

[14]  Robert C. G. Martin,et al.  Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry. , 2017, American journal of surgery.

[15]  C. Braconi,et al.  Sorafenib for the Treatment of Advanced Hepatocellular Cancer - a UK Audit. , 2017, Clinical oncology (Royal College of Radiologists (Great Britain)).

[16]  Lei Chen,et al.  New knowledge of the mechanisms of sorafenib resistance in liver cancer , 2017, Acta Pharmacologica Sinica.

[17]  A. Welm,et al.  Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer , 2016, Clinical Cancer Research.

[18]  K. Balamurugan.  HIF‐1 at the crossroads of hypoxia, inflammation, and cancer , 2016, International journal of cancer.

[19]  A. Kunnumakkara,et al.  ATP citrate lyase (ACLY): a promising target for cancer prevention and treatment. , 2015, Current drug targets.

[20]  Zhenzhen Chen,et al.  Dual-degradable disulfide-containing PEI–Pluronic/DNA polyplexes: transfection efficiency and balancing protection and DNA release , 2013, International journal of nanomedicine.

[21]  Robert V Farese,et al.  Cellular fatty acid metabolism and cancer. , 2013, Cell metabolism.

[22]  Xiaohu Zhao,et al.  Bioreducible polyethylenimine-delivered siRNA targeting human telomerase reverse transcriptase inhibits HepG2 cell growth in vitro and in vivo. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[23]  Yang Liu,et al.  A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction , 2008, Molecular Cancer Therapeutics.

[24]  Y. Yonekura,et al.  Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate. , 2004, Nuclear medicine and biology.

[25]  Suowen Xu,et al.  ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review. , 2019, Progress in lipid research.

[26]  Huafeng Zhang,et al.  Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression , 2015, Cellular and Molecular Life Sciences.